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Cancer-immunotherapy targeting programmed cell death 1 (PD-1) activates
tumor-specific T cells and provides clinical benefits in various cancers. However,
the molecular basis of PD-1 function is still enigmatic. Especially, it is unclear which
signaling pathway PD-1 primarily targets. Besides, the capacity of PD-1 to inhibit the T
cell receptor (TCR)-dependent activation of T cells in the presence of co-stimulation is
also controversial. Here we used co-culture systems of T cells and antigen-presenting
cells with targeted deletion and overexpression of co-receptors and ligands and
examined the inhibitory potency of PD-1 against T cell activation upon TCR stimulation
with CD28 and ICOS co-stimulation. As an unambiguous criterion of T cell activation,
we used the acquisition of cytokine production capacity, which represents one of the
most important functions of T cells. PD-1 inhibited functional T cell activation upon
TCR stimulation in the absence as well as in the presence of CD28 co-stimulation,
indicating that PD-1 can directly inhibit TCR signal. Notably, CD28 co-stimulation
rather attenuated the efficiency of PD-1 in inhibiting TCR-dependent functional T cell
activation. In addition, PD-1 inhibited TCR-dependent functional T cell activation with
ICOS co-stimulation as efficiently as that with CD28 co-stimulation. Furthermore, we
found that the maintenance of antigen-induced follicular helper T (TFH) cells that required
ICOS co-stimulation was persistently restrained by PD-1 in vivo. These findings indicate
that PD-1 primarily targets TCR signal in the inhibition of functional T cell activation.
Thus, PD-1 functions as the rheostat of T cell activation rather than an inhibitor of a
specific stimulatory co-receptor.
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INTRODUCTION
T cell activation initiated by antigen-dependent signals through T cell receptors (TCRs) is tightly
controlled by antigen-independent signals through stimulatory and inhibitory co-receptors to
optimize beneficial immune responses while suppressing deleterious immune responses (1–3).
Programmed cell death 1 (PD-1), one of the inhibitory co-receptors plays especially important
roles in the regulation of autoimmunity, infectious immunity, and cancer immunity. PD-1 deficient
mice develop various forms of autoimmune diseases spontaneously depending on their genetic
background and lethal inflammatory diseases upon infection with several pathogens that establish
chronic infection in PD-1-sufficient mice (4–7). In addition, cancer-immunotherapy targeting
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PD-1 activates tumor-specific T cells and eradicate tumors in
animal models as well as human patients with various cancers
(8, 9). Although the augmentation of T cell activation by PD-1
blockade is widely accepted, its molecular basis remains elusive.
PD-1 has two ligands, PD-L1 and PD-L2 that are expressed
on a variety of immune and non-immune cells. The engagement
of PD-1 with either PD-L1 or PD-L2 during antigen stimulation
leads to the phosphorylation of two tyrosine residues in
the cytoplasmic region of PD-1, the recruitment of protein
tyrosine phosphatase, SHP-2 to the distal phospho-tyrosine, and
the decreased phosphorylation of various signaling molecules
including CD3ζ, ZAP70, vav, Akt, and ERK in T cells and Igβ,
Syk, PLCγ2, and ERK in B cells (10–13). Although PD-1 has been
regarded to inhibit T cell activation by dephosphorylating these
molecules by recruiting SHP-2, the recent report by Hui et al.
demonstrated that PD-1-bound SHP-2 dephosphorylated CD28
but not CD3ζ and inducible T cell co-stimulator (ICOS), another
stimulatory co-receptor using a cell-free assay system,making the
molecular target(s) of PD-1-bound SHP-2 controversial (14).
There had been also controversial reports regarding the
capacity of PD-1 to suppress T cell activation in the presence
of co-stimulatory signals. Parry et al. reported that PD-1
inhibited CD28-mediated activation of phosphatidylinositol 3-
kinase and the subsequent Akt phosphorylation (11). On the
other hand, Bennet et al. reported that PD-1 could inhibit
TCR-dependent T cell activation with ICOS but not CD28 co-
stimulation (15). The reduced inhibitory function of PD-1 in
the presence of CD28 co-stimulation was also observed in other
studies (16, 17). In addition, most tumor cells, especially non-
hematopoietic tumor cells do not express ligands of CD28, CD80,
and CD86. Therefore, the inhibition of CD28 signal cannot be the
mechanism how PD-1 suppresses cytotoxicity against tumor cells
that express ligands of PD-1 but not those of CD28 (18). Thus, the
inhibitory potency of PD-1 against T cell activation upon TCR
stimulation with co-stimulation is currently ambiguous.
Although cell-free assay systems are useful for the precise
analyses of the physical features of proteins, some important
physiological properties of proteins including their subcellular
localization, their association to other proteins, cytoskeletal
components, and organelles, or their functional changes upon
stimulation may not be preserved properly. In addition, the
direct correlation of the transient changes in phosphorylation
levels of proteins to T cell function is not fully demonstrated.
T cell activation is a complex multistep process and the longer
and/or serial encounter of antigens over the period of hours
and days is required for the functional activation of T cells (19–
23). The recent technical advancements including TALEN and
CRISPR/Cas9 systems allow us to destroy or modify genes of
interest with high efficiency (24–27). By using these systems, we
can now directly explore the coordination of genes with high
accuracy in live cells or animals using biological functions as
readouts more easily than before.
Abbreviations:APC, antigen-presenting cell; ICOS, inducible T cell co-stimulator;
ICOSL, ligand of ICOS; KLF2, Kruppel-like factor 2; PD-1, Programmed cell death
1; TCR, T cell receptor; TFH, follicular helper T.
Here we used co-culture systems of T cells and
antigen-presenting cells (APCs) with targeted deletion and
overexpression of co-receptors and ligands to evaluate their
actual involvements in PD-1-dependent inhibition of functional
T cell activation. As an unambiguous criterion of functional T
cell activation, we used the acquisition of cytokine production
capacity, which directly reflects T cell activation and represents
one of the most important functions of T cells. Remarkably, PD-1
inhibited functional T cell activation upon TCR stimulation in
the absence as well as in the presence of CD28 co-stimulation.
Notably, CD28 co-stimulation rather attenuated the efficiency of
PD-1 in inhibiting TCR-dependent functional T cell activation.
In addition, PD-1 inhibited functional T cell activation with
ICOS co-stimulation as efficiently as that with CD28 co-
stimulation. Furthermore, we found that the maintenance of
antigen-induced follicular helper T (TFH) cells that required
ICOS co-stimulation was persistently restrained by PD-1 in vivo.
These findings indicate that PD-1 primarily targets TCR signal
in the inhibition of functional T cell activation.
MATERIALS AND METHODS
Cell Culture
DO11.10 T hybridoma, 2B4.11 T hybridoma, IIA1.6, and
CH27 cells were maintained in RPMI 1640 medium (Gibco),
supplemented with 10% (v/v) fetal bovine serum (FBS, Biowest),
0.5mM Monothioglycerol (Wako), 2mM L-alanyl-L-glutamine
dipeptide (Gibco), 100 U/ml penicillin (Nacalai Tesque), and
100µg/ml streptomycin (Nacalai Tesque). Plat-E cells were
maintained in Dulbecco’s Modified Eagle Medium (D’MEM,
Invitrogen), supplemented with 10% (v/v) FBS, 100 U/ml
penicillin (Nacalai Tesque), and 100µg/ml streptomycin
(Nacalai Tesque).
Plasmid and Retroviral Gene Transduction
Fragments of cDNA were amplified by PCR and cloned into
retroviral expression plasmid vectors modified from pFB-ires-
Neo (Agilent). For controlling the expression levels, fragments
of cDNA were cloned into retroviral expression plasmid vectors
modified from pSUPER.retro.puro (OligoEngine), the promoter
region of which was replaced with EF-1α (human elongation
factor-1 alpha) coupled with or without polyadenylation (pA)
signal. Plasmids were transfected using the FuGENE HD
(Promega) into Plat-E cells cultured in D’MEM high glucose
(Gibco) supplemented with 20% (v/v) FBS, 100 U/ml penicillin
(Nacalai Tesque), and 100µg/ml streptomycin (Nacalai Tesque)
and supernatants containing viruses were used to transduce
genes into target cells. Infected cells were selected with G418
(Wako), puromycin (Sigma-Aldrich), or blasticidin (InvivoGen).
Mice
BALB/c mice (Japan SLC) were housed under specific pathogen-
free conditions in environmentally controlled clean rooms. All
experimental procedures complied with institutional regulations
complying with the Act on Welfare and Management of
Animals and the related guidelines in Japan. All mouse protocols
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were approved by the Animal Experimentation Committee of
Tokushima University.
Flowcytometric Analysis
Cultured cells and primary T cells were stained with the
indicated Abs. Data were obtained with Gallios (Beckman
Coulter) and analyzed using FlowJo (Tree Star). Abs against
Bcl6 (K112-91) and CXCR5 (2G8) were purchased from
BD bioscience. Abs against CD3 (145-2C11), CD80 (16-10A-
1), CD86 (GL-1), and PD-L2 (TY25) were purchased from
eBioscience. The Ab against CD8 (5H10) was purchased from
Thermo Fisher Scientific. Abs against CD3 (17A2), CD4 (RM4-
5), CD28 (37.5), CD45 (30-F11), ICOS (C398.4A), ICOSL
(HK5.3), PD-1 (RMP1-30), and PD-L1 (10F.9G2), Brilliant
violet 421-conjugated streptavidin, armenian hamster IgG
(HTK888), rat IgG2b (RTK4530), and syrian hamster IgG
(SHG-1) were purchased from Biolegend. FoxP3 Transcription
Factor Staining Buffer Kit (TONBO) was used for the staining
of Bcl6.
Stimulation of T Hybridoma Cells and
Primary T Cells
DO11.10 and 2B4.11 T hybridoma cells were stimulated as
described before (28). Briefly, indicated T hybridoma cells
(5 × 104 cells/well) were stimulated with indicated APCs (1
× 104 cells/well) pulsed with indicated amount of cognate
peptide (OVA323−339 (ISQAVHAAHAEINEAGR, >95% purity,
Sigma-Aldrich Japan or eurofins Genomics) and MCC88−103
(ANERADLIAYLKQATK, >95% purity, TORAY) for DO11.10
and 2B4.11 T hybridoma cells, respectively) in 96-well round
bottom plate (BD Biosciences) for 12 to 14 h. Where indicated,
0.5µg/ml of anti-PD-L1 Ab (1-111A) (29) or mouse IgG2a
isotype control (RTK2758, Biolegend) were added. Splenocytes
and lymph node cells were stimulated with anti-CD3 Ab
(0.3µg/ml, 145-2C11) for 24 h. CD4+ and CD8+ T cells
were purified by using biotinylated Abs against CD4 (RM4-
5, Biolegend) and CD8α (53-6.7, Biolegend), respectively and
Anti-Biotin MicroBeads (Miltenyi Biotec) (>90% purity). Pre-
activated primary CD4+ T cells (2 × 104 cells/well) were
stimulated with indicated APCs (1 × 104 cells/well) pulsed
with indicated amount of anti-CD3 Ab (145-2C11) in 96-well
round bottom plate for 36 h. Pre-activated primary CD8+ T
cells (1 × 104 cells/well) were stimulated with indicated APCs
(5 × 103 cells/well) pulsed with indicated amount of anti-
CD3 Ab (145-2C11) in 96-well-round bottom plate for 36
to 48 h. The concentration of IL-2 and IFNγ in the culture
supernatant was determined by ELISA (Biolegend and Thermo
scientific, respectively).
Targeted Gene Knockout
IIA1.6 cells deficient for CD86, ICOSL and PD-L1, CH27
cells deficient for CD80, CD86, and PD-L1, and DO11.10 T
hybridoma cells deficient for CD28 were generated by using
CRISPR/Cas9 system. Guide RNA sequences targeting individual
genes (Cd274: 5′-GTATGGCAGCAACGTCACGA-3′; Cd86: 5′-
GAGACGCAAGCTTATTTCAA-3′; Cd80: 5′- GTCCAAGTC
AGTGAAAGATA-3′; Icosl: 5′-ACATGGAGCTTCTTCCAAA









C-3′; Cd28: 5′-ACTCGGCATTCGAGCGAAAC-3′ and 5′-GC
TGTTCACGCCCTTGTACA-3′) were cloned into pEF-BOS-
Cas9-U6-guide, which was modified from pEF-BOS (30) to
express humanized Cas9 cDNA (Addgene) under human EF-
1α-promoter and guide RNA under U6 promoter in opposite
directions. Plasmids were transfected into cells by electroporation
(Nucleofector II, Lonza) and cells that have lost the expression
of targeted genes were sorted by using cell sorter (MoFlo XDP,
Beckman Coulter). Clones of cells were obtained by limiting
dilution for IIA1.6-PD-L1KO, IIA1.6-PD-L1/CD86 double KO,
CH27-CD80/CD86/PD-L1 triple KO, and DO11.10-CD28KO T
hybridoma cells. IIA1.6-PD-L1/ICOSL double KO cells were
obtained by targeting ICOSL gene in IIA1.6-PD-L1KO cells
followed by cell sorting. The introduction of loss-of-function
mutations in targeted genes and the lack their expression were
confirmed by sequencing and flowcytometry, respectively.
Quantitative PCR
Total RNA was extracted from indicated cells using TRIzol
(Ambion), and then subjected to reverse transcription using
High-Capacity cDNA Reverse Transcription Kit (Applied
Biosystems). Gene expression was analyzed by quantitative
PCR (qPCR) using Power SYBR Green PCR Master mix
(Applied Biosystems) on a 7900HT Fast Real-time PCR (Applied
Biosystems). Values were normalized to the expression of Actb.
Nucleotide sequences of primer sets are listed in Table 1.
Analysis of TFH Cells
BALB/c mice were immunized subcutaneously with NP-OVA
(20 µg) emulsified in Immject alum (Thermo Fisher). On day 6
and 8 after immunization, mice were treated with indicated Ab
(anti-ICOSL Abs (HK5.3, 300 µg, Bio X cell), anti-PD-L1 Abs (1-
111A, 500 µg), or their combination) or control IgG (2A3, Bio
X cell). CD19−CD3+CD4+ T cells from popliteal lymph nodes
were analyzed by flowcytometery at day 9.
Statistics
Two-tailed unpaired Student’s t-test or one-way ANOVA with
Tukey HSD test was used to evaluate statistical significance. p <
0.05 was considered statistically significant.
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FIGURE 1 | PD-1 inhibited the antigen-dependent functional activation of DO11.10 T cells less efficiently in the presence of CD28 co-stimulation. (A) Schematic
representations of the antigen-dependent activation of DO11.10 T cells with or without CD28 engagement. (B) Expression levels of indicated co-receptors and
ligands. (C) Inhibition of antigen-dependent activation of DO11.10 T cells by PD-1 engagement. IL-2 secretion from DO11.10 T cells in the absence (white) or
presence (gray) of PD-1 engagement by PD-L1 on APCs. Anti-PD-L1 Ab completely blocked PD-1 effect (black). (D) Titration of anti-PD-L1 blocking Ab. (E)
Expression levels of CD86 on IIA1.6 cells expressing CD86 to varying degrees. (F) Antigen-dependent activation of DO11.10 T cells in the absence of CD28
co-stimulation and the enhancement of the activation in a manner dependent on the amount of CD86 on APCs. (G) Correlation between the amount of secreted IL-2
and the expression level of CD86 on APCs. (H–J) Robust PD-1-mediated inhibition of IL-2 production from DO11.10 T cells in the absence CD28 co-stimulation and
the partial attenuation of PD-1-mediated inhibitory effect by CD28 co-stimulation. IL-2 secretion from DO11.10 T cells upon stimulation with pOVA323−339-pulsed
APCs lacking (left, black and gray) or expressing (right, red and pink) CD86 in the presence (gray and pink) or absence (black and red) of PD-1 engagement (H). The
average percent PD-1-dependent inhibition of IL-2 production upon stimulation with indicated APCs pulsed with 0.3, 1, and 3µM of pOVA323−339 (I). The percent
PD-1-dependent inhibition is plotted in relation to the amount of IL-2 production in the absence of PD-1 engagement for indicated APCs (J). Data are the mean ±
SEM of technical triplicates in one experiment. Data are representative of more than two independent experiments. *p < 0.05 and **p < 0.01 by one-way ANOVA with
Tukey HSD test. Cells used in this figure are listed in Tables 2, 3.
RESULTS
Inhibition of IL-2 Production From
DO11.10T Cells by PD-1
We first tried to test whether PD-1 exclusively targets CD28
signal or not in inhibiting functional T cell activation by using
an in vitro experimental system that represents physiological
antigen-dependent activation of T cells. We used DO11.10
hybridoma T cells that recognize 323-339 segment of chicken
ovalbumin (pOVA323−339) in the context of I-A
d (Figure 1A;
Tables 2, 3) (31, 32). Upon co-culturing with pOVA323−339-
pulsed IIA1.6 B lymphoma cells that express I-Ad, DO11.10 T
cells were activated and secreted IL-2. Because the amount
of secreted IL-2 correlated with the amount of pOVA323−339,
we evaluated the strength of activation based on the amount
of secreted IL-2. DO11.10 T cells endogenously expressed
substantial amount of PD-1, whereas a low level of PD-
L1 and no PD-L2 expression could be detected on IIA1.6
cells (Figure 1B). We knocked out PD-L1 gene in IIA1.6
cells by using CRISPR/Cas9 system to obtain IIA1.6-PD-
L1KO (IIAdL1) cells. When we overexpressed PD-L1 in
IIAdL1 cells and used them (IIAdL1-PD-L1 cells) as APCs
for the stimulation of DO11.10 T cells, strong PD-1-mediated
suppression of IL-2 production was observed (Figure 1C).
Because this inhibitory effect was completely blocked by the
addition of anti-PD-L1 Ab, we evaluated the inhibitory effect of
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TABLE 2 | APCs used in this study.
PD-L1 PD-L2 CD80 CD86 ICOSL FcγRIIB
endo exo endo exo endo exo endo exo endo exo endo exo
IIA1.6 + – – – – – + – + – – – Figure 1
IIAdL1 KO – – – – – + – + – – – Figure 1
IIAdL1-PD-L1 KO + – – – – + – + – – – Figure 1
IIAdL1-PD-L1-CD86KO KO + – – – – KO – + – – – Figures 1, 2
IIAdL1-PD-L1/CD86low KO + – – – – KO low + – – – Figure 1
IIAdL1-PD-L1/CD86int KO + – – – – KO int + – – – Figure 1
IIAdL1-PD-L1/CD86high KO + – – – – KO high + – – – Figure 1
IIAdL1-PD-L1/FcgRIIB-CD86KO KO + – – – – KO – + – – + Figure 3
IIAdL1-PD-L1/FcgRIIB/CD86low KO + – – – – KO low + – – + Figure 3
IIAdL1-PD-L1/FcgRIIB/CD86high KO + – – – – KO high + – – + Figure 3
IIAdL1-ICOSLKO KO – – – – – + – KO – – – Figure 5
IIAdL1-ICOSL KO – – – – – + – KO + – – Figure 5
IIAdL1-PD-L1-ICOSLKO KO + – – – – + – KO – – – Figure 6
IIAdL1-PD-L1-ICOSL KO + – – – – + – KO + – – Figure 6
IIAdL1-PD-L1/FcgRIIB-ICOSLKO KO + – – – – + – KO – – + Figures 6, 7
IIAdL1-PD-L1/FcgRIIB/ICOSL KO + – – – – + – KO + – + Figures 6, 7
CH27 + – – – + – + – – – + – Figure 4
CH27TKO KO – – – KO – KO – – – + – Figure 4
CH27TKO-PD-L1 KO + – – KO – KO – – – + – Figure 4
CH27TKO-PD-L1/CD86 KO + – – KO – KO + – – + – Figure 4
PD-1 by comparing the presence or absence of anti-PD-L1 Ab,
hereafter (Figures 1C,D).
PD-1 Inhibited the Antigen-Dependent
Functional Activation of DO11.10T Cells
Less Efficiently in the Presence of
CD28 Co-stimulation
DO11.10 T cells endogenously expressed CD28, whereas IIA1.6
cells expressed a low amount of CD86 but did not express
CD80 (Figure 1B). We knocked out CD86 gene in IIAdL1-PD-
L1 cells to obtain IIAdL1-PD-L1-CD86KO cells (Figure 1E).
DO11.10 T cells produced a substantial amount of IL-2 upon
stimulation with pOVA323−339-pulsed IIAdL1-PD-L1-CD86KO
cells in the absence of PD-1 engagement (i.e., in the presence
of anti-PD-L1 Ab), indicating that DO11.10 T cells can be
activated in the absence of CD28 co-stimulation (Figure 1F).
Then, we overexpressed CD86 into IIAdL1-PD-L1-CD86KO
cells using weak, intermediate, and strong expression systems
to obtain IIAdL1-PD-L1-CD86low, CD86int, and CD86high cells,
respectively (Figure 1E). When we stimulated DO11.10 T cells
with these cells expressing different amounts of CD86 in the
absence of PD-1 engagement, a good correlation between the
amount of secreted IL-2 and the CD86 expression level was
observed (r = 0.985, Figures 1F,G), indicating that we could
regulate the strength of CD28 signal by changing the expression
level of CD86 on APCs.
Then we examined the effect of CD28 co-stimulation on PD-1
function. Strong PD-1-mediated suppression of IL-2 production
was observed in the absence of CD28 engagement, indicating
that PD-1 does not exclusively target CD28 signal but can
directly inhibit TCR signal with high efficiency (Figure 1H).
PD-1 also suppressed the augmented IL-2 production in
the presence of CD28 co-stimulation but the inhibitory
efficiency was rather attenuated by CD28 co-stimulation (97
and 80% inhibition with no and strong CD28 engagement,
respectively) (Figures 1H,I). By comparing the magnitude of
activation and the efficiency of PD-1-dependent inhibition
(Figure 1J), we found that PD-1 inhibited T cell activation
more efficiently in the absence of CD28 co-stimulation when
stimulatory conditions with a similar magnitude of strength
(i.e., amount of secreted IL-2) were compared. Thus, the
weaker PD-1 effect in the presence of CD28 engagement is
not simply due to the vigorous T cell activation with strong
CD28 co-stimulation.
We also tested DO11.10-CD28KO T cells to exclude the
possible effect of TCR-uncoupled engagement of CD28 in
the context of T-T interaction. PD-1 efficiently inhibited IL-2
production from DO11.10-CD28KO T cells (Figure 2; Tables 2,
3), further confirming that PD-1 can inhibit the antigen-
dependent functional activation of DO11.10 T cells in the absence
of CD28 co-stimulation.
PD-1 Inhibited the TCR-Dependent
Functional Activation of Primary T Cells
Less Efficiently in the Presence of
CD28 Co-stimulation
Then we tested the inhibitory effect of PD-1 in the absence
or presence of CD28 co-stimulation using primary T cells
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TABLE 3 | T cells used in this study.
PD-1 CD28 ICOS PKCθ
endo exo endo exo endo exo endo exo
DO11.10 + – + – – – –* – Figures 1, 2, 5
DO11.10-CD28KO + – KO – – – – – Figure 2
DO11.10-ICOS + – + – – + – – Figure 5
DO11.10-PKCθ/ICOS + – + – – + – + Figures 5, 6
2B4.11 + – + – – – –† – Figure 4
primary CD4+ – – + – – – + – Figures 3, 5, 6
primary CD8+ – – + – – – + – Figures 3, 5, 6
primary pre-activated CD4+ + – + – + – + – Figures 3, 4, 6, 7
primary pre-activated CD8+ + – + – + – + – Figures 3, 4, 6, 7
About *1/810 and
†
1/27 of primary CD4+ T cells by qPCR.
FIGURE 2 | PD-1 inhibited the antigen-dependent functional activation of
DO11.10 T cells in the absence of CD28 co-stimulation. (A) Expression levels
of CD28 on DO11.10 and DO11.10-CD28KO T cells. (B) PD-1-dependent
inhibition of the antigen-dependent functional activation of DO11.10 T cells
without CD28 co-stimulation. IL-2 secretion from DO11.10-CD28KO T cells
upon stimulation with pOVA323−339-pulsed IIAdL1-CD86KO cells in the
presence (gray) or absence (black) of PD-1 engagement. Data are the mean ±
SEM of technical triplicates in one experiment. Data are representative of three
independent experiments. Cells used in this figure are listed in Tables 2, 3.
(Figure 3A; Tables 2, 3). Because PD-1 is not expressed on
naive T cells, we induced PD-1 expression by pre-activation
with anti-CD3 Ab (Figures 3B,C). To stimulate pre-activated
primary T cells with intact APCs and engage stimulatory and
inhibitory co-receptors by native ligands (i.e., not by using
plate-bound Ab or truncated proteins tethered to synthetic lipid
bilayer), we presented anti-CD3 Ab on APCs overexpressing
FcγRIIB (33). We could observe the production of IL-2 and
IFNγ from pre-activated primary CD4+ and CD8+ T cells,
respectively in a manner dependent on the amount of anti-
CD3 Ab. PD-1 strongly suppressed the production of cytokines
from pre-activated primary CD4+ and CD8+ T cells in the
absence of CD28 co-stimulation (Figures 3D,E). As is the
case with DO11.10 T cells, the inhibitory efficiency of PD-1
was significantly attenuated in the presence of strong CD28
co-stimulation (95 vs. 40% and 71 vs. 18% inhibition of
IL-2 and IFNγ production from CD4+ and CD8+ T cells,
respectively) (Figures 3F,G).
In order to exclude the possibility that the CD28-
independency of PD-1 function is due to an unknown unique
property of IIA1.6 cells, we performed similar experiments
using another B lymphoma cells, CH27 cells as APCs. Because
CH27 cells expressed CD80, CD86, and PD-L1, we knocked out
corresponding genes by using CRISPR/cas9 system to obtain
cells lacking CD80, CD86, and PD-L1 (CH27TKO cells). Then
we overexpressed PD-L1 and CD86 into CH27TKO cells and
used them as APCs to stimulate pre-activated CD4+ and CD8+
T cells (Figures 4A–C; Tables 2, 3). PD-1 efficiently inhibited
the production of IL-2 and IFNγ from pre-activated primary
CD4+ and CD8+ T cells, respectively in the absence of CD28
co-stimulation. As is the case with IIA1.6 cells, PD-1 effects were
significantly attenuated in the presence of CD28 co-stimulation
when CH27 cells were used as APCs (Figures 4D–G). We
could also observe similar trends in PD-1 effects on the
activation of 2B4.11 T hybridoma cells upon stimulation with
CH27TKO cells pulsed with the cognate antigen (88-103
segment of moth cytochrome c, pMCC88−103) in the presence
or absence of CD28 co-stimulation (Figures 4H,I). These results
further support the idea that PD-1 can directly inhibit TCR
signal and that CD28 co-stimulation rather attenuates the
inhibitory efficiency of PD-1 on TCR-dependent functional
T cell activation.
PD-1 Efficiently Inhibited the
TCR-Dependent Functional Activation of T
Cells in the Presence of
ICOS Co-stimulation
The inhibitory capacity of PD-1 against TCR-dependent
activation of T cells with ICOS co-stimulation is also
controversial (14, 15). Therefore, we examined the inhibitory
effect of PD-1 on the functional activation of T cells in the
presence of ICOS co-stimulation. Because IIA1.6 cells expressed
the ligand of ICOS (ICOSL), we knocked out the gene encoding
ICOSL to obtain IIAdL1-ICOSLKO cells and subsequently
overexpressed ICOSL (IIAdL1-ICOSL cells). We overexpressed
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FIGURE 3 | PD-1 inhibited the TCR-dependent functional activation of primary T cells less efficiently in the presence of CD28 co-stimulation. (A) Schematic
representations of the TCR-dependent activation of primary T cells. Pre-activated CD4+ and CD8+ T cells were stimulated with anti-CD3 Ab presented on APCs with
or without CD86 expression. (B,C) Expression levels of CD28 and PD-1 on CD4+ (B) and CD8+ (C) T cells with (lower) or without (upper) pre-activation. (D–G)
Robust PD-1-mediated inhibition of cytokine production from primary T cells in the absence CD28 co-stimulation and the partial attenuation of PD-1-mediated
inhibitory effect by CD28 co-stimulation. IL-2 and IFNγ secretions from pre-activated primary CD4+ (D) and CD8+ (E) T cells, respectively upon TCR stimulation with
no (left, black and gray), weak (middle, green and olive), and strong (right, red and pink) CD28 co-stimulation. PD-1-dependent inhibitory effect was evaluated by
comparing amounts of cytokines in the presence (gray, olive, and pink) or absence (black, green, and red) of PD-1 engagement. The average percent
PD-1-dependent inhibition of cytokine production upon stimulation with indicated APCs pulsed with 0.08, 0.4, 2, and 10µg/ml of anti-CD3 Ab is shown for
pre-activated primary CD4+ (F) and CD8+ (G) T cells. Data are the mean ± SEM of technical triplicates in one experiment. Data are representative of more than two
independent experiments. **p < 0.01 by one-way ANOVA with Tukey HSD test. Cells used in this figure are listed in Tables 2, 3.
ICOS in DO11.10 T cells because its expression was lacking
(Figure 5A; Tables 2, 3). ICOS-engagement augmented IL-2
production from DO11.10 T cells in a PKCθ-dependent manner
in agreement with former reports that ICOS co-stimulation
substantially augmented IL-2 production (Figures 5B,C) (34–
36). Then we examined PD-1 effect and found that PD-1 could
strongly inhibit the IL-2 production from DO11.10 T cells upon
antigen stimulation with ICOS co-stimulation (Figure 6A;
Tables 2, 3). In contrast to CD28, the inhibitory efficiency of
PD-1 was not reduced by ICOS co-stimulation (Figure 6B).
Then we tested the inhibitory effect of PD-1 against
TCR-dependent activation of primary T cells with ICOS co-
stimulation. Because ICOS as well as PD-1 is not expressed
on naive T cells, we induced the expression of ICOS and PD-
1 by pre-activation with anti-CD3 Ab (Figures 6C,D). When
we stimulated pre-activated CD4+ and CD8+ T cells using
APCs with or without ICOSL, ICOS engagement augmented the
production of IL-2 and IFNγ from CD4+ and CD8+ T cells
up to 3.4 and 2.3-folds, respectively. PD-1 strongly suppressed
the production of cytokines from pre-activated primary CD4+
and CD8+ T cells in the presence of ICOS co-stimulation
(Figures 6E,F). The inhibitory efficiency of PD-1 in the presence
or absence of ICOS co-stimulation was also comparable in the
activation of primary T cells (Figures 6G,H).
PD-1 Restricted the Maintenance of
Antigen-Induced TFH Cells That Required
ICOS Co-stimulation
The antigen-dependent generation of TFH cells requires CD28
co-stimulation (37–39). On the other hand, their maintenance
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FIGURE 4 | Stimulation of primary T cells using CH27 B lymphoma cells as APCs. (A–C) Expression of CD80 (A), CD86 (B), and PD-L1 (C) on CH27 cells. CH27
cells endogenously express CD80, CD86, and PD-L1. Genes for CD80, CD86, and PD-L1 were knocked-out in CH27TKO cells. (D–G) Robust PD-1-mediated
inhibition of cytokine production from primary T cells in the absence of CD28 co-stimulation and the partial attenuation of PD-1-mediated inhibitory effect by
(Continued)
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FIGURE 4 | CD28 co-stimulation. IL-2 and IFNγ secretion from pre-activated primary CD4+ (D) and CD8+ (E) T cells, respectively upon TCR-stimulation in the
absence (left, black and gray) or presence (right, red and pink) of CD28 engagement. PD-1-dependent inhibitory effect was evaluated by comparing amounts of
cytokines in the presence (gray and pink) or absence (black and red) of PD-1 engagement. The average percent PD-1-dependent inhibition of cytokine production
upon stimulation with indicated APCs pulsed with 2 and 10µg/ml of anti-CD3 Ab is shown for pre-activated primary CD4+ (F) and CD8+ (G) T cells. (H,I)
PD-1-dependent inhibition of the antigen-dependent functional activation of 2B4.11 T cells without CD28 co-stimulation. CH27TKO cells with (right, red and pink) or
without (left, black and gray) CD86 were pulsed with indicated amounts of pMCC and used to stimulate 2B4.11 T cells. IL-2 secretion in the presence (gray and pink)
or absence (black and red) PD-1 engagement is shown (H). The percent PD-1-dependent inhibition denotes the average inhibitory effects with 0.3 and 1µM of pMCC
(I). Data are the mean ± SEM of technical triplicates in one experiment. Data are representative of two independent experiments. *p < 0.05 and **p < 0.01 by
two-tailed unpaired Student’s t-test. Cells used in this figure are listed in Tables 2, 3.
FIGURE 5 | ICOS engagement augmented the antigen-dependent functional activation of DO11.10 T cells in the presence of PKCθ. (A) Expression levels of ICOS and
ICOSL. (B) Increased antigen-dependent secretion of IL-2 from DO11.10-ICOS T cells by ICOS engagement in the presence of PKCθ. ICOS engagement increased
the IL-2 secretion from DO11.10-ICOS T cells overexpressing PKCθ (right) but not from DO11.10-ICOS T cells lacking PKCθ expression (left). (C) Lack of Prkcq
(PKCθ) expression in DO11.10 T cells. The expression levels of Prkcq, Zap70, and Lat in primary CD4+ and CD8+ T cells and DO11.10 T cells with or without PKCθ
overexpression were quantified by qPCR. Fold changes in expression relative to primary CD4+ T cells are shown. Data are the mean ± SEM of technical triplicates in
one experiment. Data are representative of two independent experiments. Cells used in this figure are listed in Tables 2, 3.
requires ICOS but not CD28 co-stimulation (40–44). PD-
1 is highly expressed on TFH cells and has been shown to
regulate the function of TFH cells (37). In order to confirm
that PD-1 can inhibit the functional T cell activation upon
TCR signal co-stimulated by ICOS in vivo, we examined the
effect of PD-1 on the maintenance of TFH cells. We immunized
mice with NP-OVA, a T-dependent antigen to induce germinal
center reaction (Figure 7A). In agreement with the former
report (44), the administration of anti-ICOSL blocking Ab
during the maintenance phase of TFH cells (6 and 8 days
after immunization) markedly decreased the frequency and the
number of TFH cells (1.0 vs. 0.18 % and 6.9 vs. 1.2× 10
4 cells for
control IgG- and anti-ICOSL Ab-treated mice, respectively). In
contrast, the administration of anti-PD-L1 blocking Ab during
the maintenance phase of TFH cells significantly increased the
frequency and the number of TFH cells (1.0 vs. 1.5 % and 6.9
vs. 10.1 × 104 cells for control IgG- and anti-PD-L1 Ab-treated
mice, respectively) (Figures 7B–E). These results suggest that
the maintenance of TFH cells by TCR signal co-stimulated by
ICOS is persistently weakened by PD-1 to restrict the number
of TFH cells, which is in agreement with former reports that
TFH cells with lower affinity were increased in the absence of
PD-1 (45–47).
PD-1 Partially Attenuated the
Down-Regulation Klf2 Upon TCR
Stimulation With ICOS Co-stimulation
The maintenance of TFH cells by ICOS has been reported
to depend on the facilitation of TCR-dependent reduction
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FIGURE 6 | PD-1 efficiently inhibited the functional activation of DO11.10 and primary T cells upon TCR stimulation with ICOS co-stimulation. (A,B) PD-1-dependent
inhibition of the functional activation of DO11.10 T cells upon antigen stimulation with ICOS co-stimulation. IL-2 secretion from DO11.10 T cells upon stimulation with
pOVA323−339-pulsed APCs lacking (left, black and gray) or expressing (right, red and pink) ICOSL in the presence (gray and pink) or absence (black and red) of PD-1
engagement (A). The average percent PD-1-dependent inhibition of IL-2 production upon stimulation with indicated APCs pulsed with 0.3, 1, and 3µM of
pOVA323−339 (B). (C,D) Expression levels of ICOS and PD-1 on CD4
+ (C) and CD8+ (D) T cells with (lower) or without (upper) pre-activation. (E–H)
PD-1-dependent inhibition of the functional activation of primary T cells upon TCR stimulation with ICOS co-stimulation. IL-2 and IFNγ secretion from pre-activated
primary CD4+ (E) and CD8+ (F) T cells, respectively upon TCR stimulation in the absence (left, black and gray) or presence (right, red and pink) of ICOS
co-stimulation. PD-1-dependent inhibitory effect was evaluated by comparing amounts of cytokines in the presence (gray and pink) or absence (black and red) of
PD-1 engagement. The average percent PD-1-dependent inhibition of cytokine production upon stimulation with indicated APCs pulsed with 2 and 10µg/ml of
anti-CD3 Ab is shown for pre-activated primary CD4+ (G) and CD8+ (H) T cells. Data are the mean ± SEM of technical triplicates in one experiment. Data are
representative of more than two independent experiments. Cells used in this figure are listed in Tables 2, 3.
of Kruppel-like factor 2, a zinc-finger transcription factor
(KLF2, Klf2) by ICOS co-stimulation (44, 48). Therefore,
we examined the effect of PD-1 on the expression of Klf2
by stimulating pre-activated CD4+ T cells in conditions
involving PD-1 and/or ICOS (Figures 7F–H; Tables 2, 3). In
agreement with the former report, we observed the facilitation
of TCR-dependent reduction of Klf2 expression by ICOS
engagement (44). In addition, ICOS engagement augmented
the TCR-dependent up-regulation of Il21 and Il4, which are
required for the function of TFH cells. Remarkably, PD-1
blockade in the presence of ICOS co-stimulation further
facilitated the TCR-dependent down-regulation of Klf2 and
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FIGURE 7 | PD-1 restricted the maintenance of antigen-induced TFH cells that required ICOS co-stimulation. (A) Schematic representation of the experimental
system to analyze PD-1 effects on the maintenance of antigen-induced TFH cells. Anti-ICOSL and anti-PD-L1 Abs were administrated independently or in
combination on days 6 and 8 to analyze their effects on the maintenance of antigen-induced TFH cells. CD4
+ T cells in draining lymph nodes were analyzed on day 9.
(B–E) Increase of TFH cells by PD-1 blockade during their maintenance phase. Representative flowcytometric profiles (B,C) and statistics (D,E) of TFH cells identified
by the expression of CXCR5 and PD-1 (B,D) and CXCR5 and Bcl6 (C,E) are shown for mice with the indicated treatment. (F–H) PD-1 blockade facilitated the
down-regulation of Klf2 (F) and up-regulation of Il4 (G) and Il21 (H) upon TCR stimulation with ICOS co-stimulation. Pre-activated primary CD4+ T cells were
stimulated with anti-CD3 Ab (2C11, 0.1µg/ml) in the indicated combination of ICOS and PD-1 engagements for 6 h. T cells were purified and the expression of Klf2,
Il4, and Il21 was quantified by qPCR. Data are the mean ± SEM of technical triplicates in one experiment. Data are representative of more than two independent
experiments. *p < 0.05 and **p < 0.01 by one-way ANOVA with Tukey HSD test. Cells used in this figure are listed in Tables 2, 3.
up-regulation of Il21 and Il4, in accordance with the increase
of TFH cells by PD-1 blockade in vivo (Figures 7F–H).
Therefore, PD-1 likely restricts the generation of TFH cells
by restraining the down-regulation of Klf2 upon TCR
stimulation with ICOS co-stimulation during the germinal
center reaction.
DISCUSSION
In the current study, by taking the advantage of the in vitro and
ex vivo co-culture systems of T cells and APCs and the genome-
editing technology, we directly tested the molecular coordination
of PD-1 and stimulatory co-receptors in the functional activation
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of T cells. We clearly demonstrated that PD-1 could inhibit
cytokine production from T cells upon activation in the absence
as well as in the presence of CD28 co-stimulation. Meanwhile,
PD-1 inhibited functional T cell activation with ICOS co-
stimulation as efficiently as that with CD28 co-stimulation. In
addition, we found that the maintenance of TFH cells that
depended on TCR signal co-stimulated by ICOS was persistently
restrained by PD-1 in vivo. Stimulatory co-receptors depend on
TCR signal for their activation and function by reinforcing TCR
signal (1, 3). Therefore, the most straightforward interpretation
of aforementioned results is that PD-1 primarily inhibits TCR
signal. Thus, PD-1 functions as a rheostat of T cell activation
rather than an inhibitor of a specific stimulatory co-receptor.
Intriguingly, the inhibitory efficiency of PD-1 was substantially
lower in the presence of CD28 co-stimulation, suggesting that the
CD28 signaling pathway is rather resistant to PD-1 and/or CD28
co-stimulation renders TCR signal resistant to PD-1.
Bennet et al. reported that PD-1 could inhibit T cell activation
with ICOS but not CD28 co-stimulation (15). On the other
hand, Hui et al. reported that PD-1 dephosphorylated CD28
but not CD3ζ and ICOS using a cell-free assay system. The
preferential dephosphorylation of CD28 by PD-1 was also
demonstrated in Jurkat cells in the latter study. However, the
dephosphorylation of CD28 was observed only transiently and
CD28 was phosphorylated to a similar level in the absence or
presence of PD-1 by 10min after TCR stimulation (14). T cell
activation is a complex multistep process and the longer and/or
serial encounter of antigens over the period of hours and days
is required for the functional activation of T cells (19–23). Thus,
the transient and the moderate difference in the phosphorylation
level of CD28 may not represent the actual effect of PD-1 on the
functional activation of T cells. In addition, the target specificity
may not be preserved in the cell-free assay system enough.
Actually, CD45, a receptor-type protein tyrosine phosphatase
that is known to dephosphorylate Y505 of Lck at the early phase
of T cell activation (49) dephosphorylated broader targets and
showed similar preference to CD28 in the cell-free assay (14).
Although CD45 is segregated from the center of the immune
synapse during T cell activation (50, 51), the segregation might
not occur properly in the cell-free assay.
In the current study, by using the acquisition of cytokine
production capacity that directly reflects T cell activation and
represents one of the most important functions of T cells as
an unambiguous benchmark of functional T cell activation, we
clearly demonstrated that PD-1 did not exclusively target CD28
signal and that CD28 co-stimulation was rather prohibitive for
PD-1 function.
In line with the preferential dephosphorylation of CD28 by
PD-1 in the aforementioned cell free assay (14), Kamphorst
et al. demonstrated that the blockade of CD80/CD86
attenuated the therapeutic effects of anti-PD-L1 Ab against
CT26 colon tumor cells (52). Although their observation
clearly supports the conclusion that CD28-dependent co-
stimulation is required for the re-activation of PD-1+ T
cells by PD-1 blockade, it does not necessarily argue for the
inhibition of CD28 signal by PD-1 or deny the inhibition
of TCR signal by PD-1 in the eradication of tumor cells
(18). It should also be noted that CT26 cells strongly express
CD80 (53), and thus, might be affected by CD28-blockade
more strongly than tumor cells without CD80 expression.
Meanwhile, current findings do not preclude the requirement
of CD28 co-stimulation in the re-activation of exhausted
PD-1+ T cells.
The recent success of cancer immunotherapies targeting
PD-1 and the development of autoimmune diseases as their
immune related adverse events revealed that PD-1 plays critical
roles in the regulation of T cells specific to self antigens
as well as tumor-associated antigens in humans. Extensive
trials of combinatorial therapies targeting multiple inhibitory
and stimulatory co-receptors are ongoing to increase the
efficacy of cancer immunotherapies while minimizing immune
related adverse events. Precise and deeper understandings of
the inhibitory mechanisms of PD-1 will support the rational
development of immuno-modulatory therapies for a diverse
array of diseases.
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